Meeting
2022 ASCO Annual Meeting
A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.
Authors
Serigne N. Lo
Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
Serigne N. Lo , Tuba Nur Gide , Maria Gonzalez , Ines Silva , Alexander M. Menzies , Matteo S. Carlino , Richard A. Scolyer , Stephane Heritier , James S. Wilmott , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9599)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9599
Abstract #
TPS9599
Poster Bd #
188a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.
First Author: Hazel Lote
Poster
2022 ASCO Annual Meeting
Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.
First Author: Brian Gastman
Poster
2021 ASCO Annual Meeting
Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.
First Author: Ivan Marquez-Rodas
Poster
2015 ASCO Annual Meeting
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal